Country: Japan

Shin-Nippon: Nasal Drug Delivery

The Translational Research (TR) Company, a division of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), has developed a proprietary nasal drug delivery platform known as the μco™ system (“myu-co”). This innovative system integrates two core components: advanced powder carrier technology and a specialized delivery device.

Beyond licensing this platform and its in-house developed products to pharmaceutical companies, SNBL also provides comprehensive support for pharmaceutical research and development. Leveraging the Group’s extensive expertise as a Contract Research Organization (CRO), SNBL utilizes its globally recognized, cutting-edge preclinical and clinical research facilities to drive efficient and high-quality drug development.